Market Place
Sourcing Support
Alkem Labs Generic Elagolix Receives Tentative Approval in US
12 Jun 2024 //
FDA
Elagolix Sodium: A Breakthrough in Endometriosis and Uterine Fibroid Management
06 Jun 2024 //
PRESS RELEASE
Silodosin,Elagolix sodium,Daprodustat & Vonprazon Fumarate Gained WC certificate
04 Jun 2024 //
PRESS RELEASE
Under hub-and-spoke biotech, serial founders launch new startup gene therapies
31 Oct 2022 //
ENDPTS
AbbVie puts up fight against Orilissa generics from Sandoz, Teva and others
31 Oct 2022 //
ENDPTS
AbbVie Sues to Block Copies of Orilissa Endometriosis Drug
29 Oct 2022 //
BLOOMBERGLAW
FDA Confirms Paragraph IV Patent Litigation for Orilissa (Elagolix)
22 Sep 2022 //
FDA
Enforcement Report - Week of June 2, 2021
02 Jun 2021 //
FDA
Myovant shows disappointing prostate cancer data on the way to the FDA
30 Sep 2020 //
ENDPTS
FDA approves Abbvie`s drug to control menstrual bleeding due to fibroids
01 Jun 2020 //
FDA
AbbVie scores `game-changer` nod for Oriahnn in uterine fibroids
01 Jun 2020 //
FIERCE PHARMA
AbbVie wins an approval in uterine fibroid-associated heavy bleeding Myovant
29 May 2020 //
ENDPTS
Myovant Squares Off with AbbVie On Endometriosis Treatment
27 Apr 2020 //
FOOL
AbbVie Files for FDA Approval of Elagolix for Uterine Fibroids
13 Aug 2019 //
ENDOMETROSISNEWS
Myovant hits goal in uterine fibroid phase 3
15 May 2019 //
FIERCE BIOTECH
Neurocrine flags a failure for Tourette syndrome study — shares sink
13 Dec 2018 //
ENDPTS
AbbVie`s Orilissa makes its uterine fibroids case with double phase 3 win
16 Nov 2018 //
FIERCE PHARMA
AbbVie preps uterine fibroid filing after phase 3 win
15 Nov 2018 //
PM LIVE
AbbVie saves 96% on taxes in the first 9 months after tax reform
03 Nov 2018 //
FIERCE PHARMA
FDA turns thumbs down on Allergan’s optimistic case for uterine fibroid drug
22 Aug 2018 //
ENDPTS
AbbVie`s Orilissa shouldn`t be first in line for endometriosis treatment: ICER
08 Aug 2018 //
FIERCE PHARMA
Would AbbVie’s top execs pull the trigger on a $30B M&A deal?
31 Jul 2018 //
ENDPTS
AbbVie prices new endometriosis drug at $10,000 a year
26 Jul 2018 //
REUTERS
ICER Report Suggest AbbVie’s Elagolix Could Strain Healthcare Budgets
09 May 2018 //
BIOSPACE
US delay for AbbVie/Neurocrine’s uterine pain drug
12 Apr 2018 //
PHARMA TIMES
FDA needs more time to review AbbVie, Neurocrine`s uterine pain drug
11 Apr 2018 //
REUTERS
AbbVie, Neurocrine’s fibroid drug hits PhIII targets
15 Mar 2018 //
PHARMA TIMES
AbbVie Announces +ve Topline Results from IInd Ph3 Study Evaluating Inv Elagolix
13 Mar 2018 //
PR NEWSWIRE
AbbVie sweeps back PhIIIs for uterine fibroid patients, adding to elagolix’s
13 Mar 2018 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.